Benjamin Graham Detailed Fundamental Analysis

According to Validea's guru fundamental report, Intuitive Surgical (ISRG) receives a 71% rating based on Benjamin Graham's value investing strategy, which favors companies with low price-to-book and price-to-earnings ratios, low debt, and strong long-term earnings growth; ISRG passes Graham's criteria for sales, current ratio, long-term debt, and EPS growth, but fails the P/E and price-to-book ratio tests.

Analysis

Intuitive Surgical Inc. (ISRG), a large-cap growth stock in the Medical Equipment & Supplies industry, scores 71% under Validea's Value Investor model based on Benjamin Graham's deep value strategy. This methodology prioritizes low price-to-book (P/B) and price-to-earnings (P/E) ratios, minimal debt, and consistent long-term earnings growth. ISRG meets Graham's criteria concerning its sales, current ratio, long-term debt relative to net current assets, and long-term EPS growth. However, the company fails the tests for P/E ratio and P/B ratio, indicating that its current market valuation does not align with Graham's traditional value benchmarks. A score of 71% suggests the strategy has limited interest, as it falls below the 80% threshold for 'some interest' and significantly below the 90% level for 'strong interest'. The mixed overall sentiment score of 0.05 and a per-ticker sentiment of 0.2 for ISRG reflect this dichotomy between strong underlying fundamentals and higher valuation multiples.

Key Decisions for Investors

• Investors adhering strictly to Benjamin Graham's deep value principles should note ISRG's failure on key valuation metrics like P/E and P/B ratios, despite its strengths in sales, debt management, and EPS growth.
• Consider whether ISRG's classification as a growth stock and its performance in the Medical Equipment & Supplies sector justify valuation multiples that are higher than what a traditional Graham value screen would favor.
• Monitor if future earnings growth or market corrections bring ISRG's P/E and P/B ratios to levels more attractive to value investors, or alternatively, assess if its fundamental strengths warrant an investment despite not meeting all Graham criteria.